Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Caitlin Truesdale

LambdaVision sets sights on artificial retina

LambdaVision’s signature product — an artificial retina that could change the lives of thousands with degenerative eye diseases — is under development aboard the International...

| By Caitlin Truesdale

Biohaven’s Nurtec decreases opioid use re migraine

New data show that migraine patients treated with Biohaven’s Nurtec ODT decreased their use of opioids. “Results demonstrate a clinically meaningful reduction in opioid use in...

| By Caitlin Truesdale

Yale venture to promote innovation, entrepreneurship

Yale has announced an ambitious new initiative to support and expand innovation and entrepreneurship across the university and throughout the greater New Haven region. Yale Ventures will...

| By Caitlin Truesdale

Weekly Roundup – April 20, 2022 

View this email in your browser Weekly Roundup – April 20, 2022                           ...

| By Caitlin Truesdale

Bioasis in research collaboration with Janssen

Bioasis has entered into a research collaboration with Janssen Biotech, one of the pharmaceutical companies of Johnson & Johnson. Under the terms of the agreement, Janssen...

| By Caitlin Truesdale

BioCT welcomes new member Sino Biological

As a high-tech enterprise, Sino Biological specializes in the research, development, production and sales of biological reagents such as recombinant proteins, antibodies, genes and culture media. The...

| By Caitlin Truesdale

Sema4 co-authors study on lung cancer therapy

Stamford-based Sema4, working in partnership with researchers from the Icahn School of Medicine at Mount Sinai in New York City, have published a study in Nature...

| By Caitlin Truesdale

BioCT welcomes new member New Haven Promise

New Haven Promise builds a college-going, career, and civic-launch culture throughout the city of New Haven in which students in the public schools aspire to attend...

| By Caitlin Truesdale

Alexion to expand New Haven footprint

Alexion, AstraZeneca’s Rare Disease group, plans to expand its presence in New Haven with space at the new bioscience tower currently under construction at 101...

| By Caitlin Truesdale

FDA approves agitation treatment from BioXcel

The FDA has approved a drug from New Haven-based BioXcel Therapeutics for the treatment of agitation associated with schizophrenia or bipolar disorder in adults. The FDA ruled that...